Approval · Notice of Compliance 24917 · 2021
APO-INDAPAMIDE: Notice of Compliance 24917
Issued January 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24917
- Date
- January 4, 2021
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph
- Canadian reference product
- LOZIDE (Servier Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-INDAPAMIDE | Not yet assigned | — |
Medicinal ingredients
- INDAPAMIDE 1.25 MG per TAB
- INDAPAMIDE 2.5 MG per TAB